

Long-term outcome of a randomized controlled study in patients with newly diagnosed severe aplastic anemia treated with antithymocyte globulin and cyclosporine, with or without granulocyte colony-stimulating factor: a Severe Aplastic Anemia Working Party Trial from the European Group of Blood and Marrow Transplantation

André Tichelli,¹ Régis Peffault de Latour,² Jakob Passweg,¹ Cora Knol-Bout,³ Gérard Socié,⁴ Judith Marsh,⁵ Hubert Schrezenmeier,⁶ Britta Höchsmann,⁶ Andrea Bacigalupo,⁷ Sujith Samarasinghe,⁸ Alicia Rovó,⁹ Austin Kulasekararaj,¹⁰ Alexander Röth,¹¹ Dirk-Jan Eikema,³ Paul Bosman,³ Peter Bader,¹² Antonio Risitano¹³ and Carlo Dufour¹⁴ on behalf of the SAA Working Party of the EBMT

¹Division of Hematology, University Hospital Basel, Basel, Switzerland; ²Université de Paris, and Hematology-Transplantation, Saint Louis Hospital (AP-HP), Paris, France; ³EBMT Registry Office, Leiden, the Netherlands; ⁴Université de Paris, INSERM U976 and Hematology-Transplantation, Saint Louis Hospital (AP-HP), Paris, France; ⁵Department of Haematological Medicine, King's College Hospital/King's College London, London, UK; ⁶Institute of Transfusion Medicine, University of Ulm and Institute of Clinical Transfusion Medicine and Immunogenetics Ulm, German Red Cross Blood Transfusion Service Baden-Württemberg-Hessen and University Hospital Ulm, Ulm, Germany; ⁷Instituto di Ematologia, Fondazione Policlinico Universitario Gemelli IRCSS, Università Cattolica del Sacro Cuore, Roma, Italy; ⁸Sujith Samarasinghe, Great Ormond Street Hospital, London, UK; ⁹Department of Hematology and Central Hematology Laboratory, Bern University Hospital, University of Bern, Bern, Switzerland; ¹⁰Department of Haematological Medicine, King's College Hospital, NIHR/Wellcome King's Clinical Research Facility, London, UK; ¹¹Department of Hematology, West German Cancer Center, University Hospital Essen, University of Duisburg-Essen, Essen, Germany; ¹²University Children's Hospital Frankfurt, Frankfurt, Germany; ¹³Hematology Department of Clinical Medicine and Surgery, Federico II University of Naples, Naples, Italy and ¹⁴Hemato-Onco-SCT Pole, Hematology Unit. G. Gaslini Children's Research Hospital, Genova, Italy.

©2020 Ferrata Storti Foundation. This is an open-access paper. doi:10.3324/haematol.2019.222562

Received: March 20, 2019.

Accepted: September 30, 2019.

Pre-published: October 3, 2019.

Correspondence: *ANDRÉ TICHELLI* - tichelli@datacomm.ch

Online supplemental material

Appendix: Participating Centers:

Germany

Universitätsklinikum Ulm, University Hospital Essen; Charité-Campus Benjamin Franklin Berlin; Hannover Medical School; Klinikum Nürnberg; University Hospital Cologne; Universitätsklinikum Düsseldorf; Katholisches Krankenhaus Hagen; Universitätsklinikum Rostock; Universitätsklinikum Tübingen; Dr. Horst-Schmidt-Kliniken Wiesbaden; Klinikum Oldenburg; HELIOS Klinikum Wuppertal; Krankenhaus München Schwab; Klinikum Harlaching München; University Hospital Regensburg; Charité-Campus Virchow Klinikum Berlin; Universitätsklinikum Dresden; Klinikum Rechts der Isar München; Diako Krankenhaus Bremen; Katharinenhospital Stuttgart; Robert-Bosch-Krankenhaus Stuttgart; Universitätsklinikum Frankfurt (am Main); Deutsche Klinik für Diagnostik Wiesbaden; Asklepios Klinik Altona Hamburg; Katholisches Klinikum Duisburg; Universitätsklinikum Halle; Klinikum der Stadt Ludwigshafen, Sana Kliniken Lübeck; St.-Antonius-Hospital Eschweiler; Park-Krankenhaus Leipzig; St.-Marien-Hospital Hamm, Evangelisches Waldkrankenhaus Spandau.

France

Hôpital Henri Mondor Creteil; Hôpital St. Louis Paris; Hôpital Robert Debré Reims; University Hospital Caremeu Nîmes; Hôpital Saint Antoine Paris; Hôpital Bretonneau Tours; CHU Lapeyronie Montpellier; CHRU Limoges; Hôpital Côte de Nacre Caen; Hôpital Beaujon Clichy; Hôpital Morvan Brest; Hôpital Avicenne Bobigny.

Italy

San Martino Hospital Genova; Giannina Gaslini Children's Hospital Genova; San Raffaele Scientific Institute Milan; Clinica di Oncoematologia Pediatrica Padova.

United Kingdom

St. George's Hospital London; Bristol Royal Hospital for Children; Monklands Hospital Airdrie; St. Barth's Hospital London.

Greece

St. Sophia Children's Hospital Athens; Patras University Medical School.

The Netherlands

University Medical Center Groningen; Leiden University Medical Center.

Switzerland

University Hospital Basel.


Czech Republic

Charles University Hospital Pilsen.

Supplemental Figure 1A

Overall survival of patients treated with horse ATG and Cyclosporine A, with or without G-CSF, according to severity of the disease.

SAA, severe aplastic anemia; vSAA, very severe aplastic anemia.



Supplemental Figure 1B

Overall survival of patients surviving 1 year or longer after treatment with horse ATG and Cyclosporine A, with or without G-CSF, according to severity of the disease. Severity of the disease does no longer impact on patients surviving 1 year or longer after treatment with ATG and Cyclosporine A.

SAA, severe aplastic anemia; vSAA, very severe aplastic anemia.

